Click here to view online. Add this email to your safelist.

AstraZeneca logo

Bevespi Aerosphere™ approved by the US FDA for patients with COPD

25 April 2016

AstraZeneca today announced that the US Food and Drug Administration has approved Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2015

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.